Moneycontrol PRO
HomeNewsTrendsHealthCoronavirus pandemic | Data from COVID-19 vaccine's phase-1 trials to be out in a month: AstraZeneca

Coronavirus pandemic | Data from COVID-19 vaccine's phase-1 trials to be out in a month: AstraZeneca

Pharmaceutical and biopharmaceutical company AstraZeneca is expected to start working manufacturing capabilities once the late stage of the COVID-19 vaccine's trials begin.

May 14, 2020 / 09:06 IST
Representative image

AstraZeneca, which is partnering with the University of Oxford to develop a potential COVID-19 vaccine, has said that the data from phase-I trials will be available in a month, according to a report by Business Standard.

The company has also said that late-stage trials should take place by the middle of this year.

The pharmaceutical and biopharmaceutical company is expected to start working manufacturing capabilities once the late stage trials begin.

Once the vaccine is proven to be successful, the company will reportedly use all manufacturing sites available globally, including those in the United States, the United Kingdom and China.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The phase-I trails of potential vaccines against COVID-19, known as ChAdOx1 nCoV-19, are currently happening at five centres in England, the report suggests.

ChAdOx1 nCoV-19 is being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford.

Also read: These four COVID-19 vaccines are ahead of the pack

The vaccine uses weakened version of chimpanzee adenovirus as vector, infused with the genetic material of SARS-CoV-2 spike protein. Adenovirus causes common cold. After vaccination, the SARS-CoV-2 surface spike protein is produced, which alerts the immune system to attack the virus causing COVID-19.

University of Oxford has been working on vaccines on MERS (Middle East Respiratory Syndrome) and Severe Acute Respiratory Syndrome (SARS), diseases which are caused by coronaviruses.

Click here for Moneycontrol’s full coverage of the novel coronavirus pandemic

Moneycontrol News
first published: May 14, 2020 09:06 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347